v3.26.1
Segment Reporting (Tables)
6 Months Ended
Jun. 30, 2026
Segment Reporting  
Schedule of segment significant expense categories

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Six Months Ended June 30, 

​

​

2026

​

2025

Grant income

​

$

7,497

​

$

12,192

Less:

​

 

​

​

 

​

Clinical programs

​

​

6,238

​

​

15,051

R&D Personnel costs(1)

​

​

3,352

​

​

4,973

Preclinical programs

​

​

682

​

​

225

Manufacturing

​

​

583

​

​

1,150

Other research and development expenses

​

​

92

​

​

227

General and administrative expenses(2)

​

​

4,959

​

​

4,920

Equity-based compensation

​

​

649

​

​

1,207

Other segment items(3)

​

 

(556)

​

 

(347)

Segment and consolidated net loss

​

$

(8,502)

​

$

(15,214)

(1) R&D Personnel costs exclude equity-based compensation

(2) General and administrative expenses exclude equity-based compensation

(3) Other segment items include, Other income, net, and Interest expense